Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

Study Summary

This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX007 in adults with metastatic castration-resistant prostate cancer (mCRPC).

Conditions

Prostate Cancer Metastatic Castration-resistant Prostate Cancer Castration Resistant Prostatic Cancer

Interventions / Drugs

JANX007 Darolutamide

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment272 participants

Primary Completion—

Lead SponsorJanux Therapeutics

Data Retrieved2026-04-11 04:18:24.248766+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.